Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24436396 | 0.96 | KRAS (0.78) | KRAS | |
| SCHEMBL24436136 | 0.95 | KRAS (0.81) | KRAS | |
| SCHEMBL24436398 | 0.93 | KRAS (0.79) | KRAS | |
| SCHEMBL24436157 | 0.93 | KRAS (0.76) | KRAS | |
| SCHEMBL23272791 | 0.92 | KRAS (0.80) | KRAS | |
| SCHEMBL24436208 | 0.92 | KRAS (0.80) | KRAS | |
| SCHEMBL24436445 | 0.92 | KRAS (0.68) | KRAS | |
| SCHEMBL24436397 | 0.92 | KRAS (0.81) | KRAS | |
| SCHEMBL24436385 | 0.92 | KRAS (0.79) | KRAS | |
| SCHEMBL24436254 | 0.92 | KRAS (0.68) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| WO-2020259513-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.